ABX464: Clinical Trials

12 trials of ABX464, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 12 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 9, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 32Terminated 1, Withdrawn 1
Phase 11Completed 1

Follow ABX464: new trials by email Literature Review of ABX464 trials Research Report on ABX464

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
ABX464, Placebo - Crohn Disease
Phase 2 / Phase 3WithdrawnAbivax S.A.2022-09-192024-07-31
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
ABX464 - Ulcerative Colitis
Phase 2Active not recruitingAbivax S.A.2032021-12-032026-04-27
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
ABX464, Placebo - COVID-19
Phase 2 / Phase 3TerminatedAbivax S.A.5092020-07-012025-11-26
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
ABX464 - Ulcerative Colitis
Phase 2CompletedAbivax S.A.2172020-01-132026-05-06
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
ABX464 - Rheumatoid Arthritis
Phase 2CompletedAbivax S.A.402019-10-252025-11-17
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
ABX464 100 mg, ABX464 50 mg, ABX464 25 mg - Ulcerative Colitis
Phase 2CompletedAbivax S.A.3552019-08-132025-11-28
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
ABX464 50mg, Matching Placebo, ABX464 100mg - Rheumatoid Arthritis
Phase 2CompletedAbivax S.A.602019-07-042023-02-15
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
ABX464 - Ulcerative Colitis
Phase 2CompletedAbivax S.A.222018-01-202025-05-29
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
ABX464, Placebo oral capsule - Ulcerative Colitis
Phase 2CompletedAbivax S.A.322017-11-162024-06-03
A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
ABX464 150mg, ABX464 50mg - HIV Infections, Health Volunteers
Phase 1 / Phase 2CompletedAbivax S.A.362017-03-272023-03-31
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
ABX464, Placebo - HIV Infection
Phase 2CompletedAbivax S.A.302016-05-012024-09-19
Safety, PK and PD Study of ABX464 in Untreated HIV Patients
ABX464, Placebo - Human Immunodeficiency Virus Infections
Phase 2CompletedAbivax S.A.702015-01-012016-05-30

Conditions studied

Colitis, Ulcerative (5)  ·  Arthritis, Rheumatoid (2)  ·  HIV Infections (2)  ·  COVID-19 (1)  ·  Crohn Disease (1)

Sponsors

Abivax S.A. (12)

Countries

Belgium (10)  ·  France (8)  ·  Spain (7)  ·  Hungary (6)  ·  Poland (6)  ·  Czechia (5)  ·  Germany (5)  ·  Austria (4)  ·  Italy (4)  ·  Canada (3)  ·  Serbia (3)  ·  Slovakia (3)  ·  Slovenia (3)  ·  Ukraine (3)  ·  United Kingdom (3)

Top investigators

Bram Verstockt, MD (1)  ·  Laurence Desroys du Roure, PharmD (1)

Results publications

PMID 28507108, PMID 30800421, PMID 34436569, PMID 35641124, PMID 36075249, PMID 40417999